How much does the generic version of Osimertinib (Tagressa) cost?

Osimertinib (Tagrisso) is a drug widely used to treat non-small cell lung cancer (NSCLC). It belongs to a class of drugs called epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, which are commonly used to treat patients with advanced NSCLC patients who are positive for EGFR gene mutations.

Osimertinib (Tagressa) has now been launched in the Chinese market and has also been included in the medical insurance system. Patients can easily buy it at pharmacies in domestic hospitals, and the price is in the range of four to five thousand yuan. However, you need to consult your local hospital pharmacy for the specific amount and detailed policy on medical insurance reimbursement.

In addition, if you are looking for more economical options, foreignOsimertinib (Tagrisso) generic drugs will be a direction to consider. In particular, the price of generic drugs produced in Laos and Bangladesh is only about a few hundred yuan, which is far lower than the domestic market price. It is worth mentioning that the ingredients of these generic drugs are almost the same as those of domestic original drugs.

EGFRgene mutation is a common molecular abnormality in NSCLC, especially in Asian populations. These mutations can promote cancer development by causing tumor cells to grow and divide excessively. The mechanism of action of Osimertinib (Tagressa) is to inhibit the abnormal activation of EGFR receptors and block the growth signaling of cancer cells, thereby inhibiting the growth and spread of tumors.

Compared with otherEGFRinhibitors,osimertinib (Tagrisso)has higher selectivity and more effectively inhibits the activity ofEGFR mutant strains while having less impact on normal cells, thereby reducing the occurrence of side effects. This makes Osimertinib (Tagrisso) one of the first-line drug options for the treatment of EGFR mutation-positive NSCLC.

In clinical studies,osimertinib (Tagrisso) has been shown to be effective in the treatment of EGFR T790Mmutation-positive advanced NSCLCSignificant efficacy has been demonstrated in patients. In addition, it is also widely used in the first-line treatment of EGFR sensitive mutations. Some studies have also shown that osimertinib (Tagressa) is also effective in treating brain metastases because of its ability to penetrate the blood-brain barrier and inhibit tumor growth in the brain.